Our objective was to audit our current stress ulcer prophylaxis protocol (routine prescription of ranitidine and early enteral feeding) by identifying whether routine prescription of histamine-2 receptor antagonists or proton pump inhibitors as prophylaxis against stress-related mucosal disease and subsequent upper gastrointestinal bleeding is supported in the literature. We also aimed to ascertain what literature evidence supports the role of early enteral feeding as an adjunctive prophylactic therapy, as well as to search for burn-patient specific evidence, since burn patients are at high risk for developing this condition, with the aim of changing our practice.
CONTEXT
In a decade of burn care at the Royal Adelaide Hospital in South Australia, there have been only two patients (of over 3000) who have displayed clinical evidence of upper gastrointestinal bleeding, with ulceration identified at endoscopy. During this time, all patients admitted to the burns unit with burn injury requiring fluid resuscitation (>15% total body surface area, [TBSA]) routinely received stress ulcer prophylaxis with ranitidine 150 mg, twice daily, from admission to discharge. One of the two patients mentioned had the ranitidine replaced with pantoprazole by our gastroenterological colleagues, who after endoscopic confirmation of ulceration advised us that our prophylaxis regimen was outdated and that proton pump inhibitors (PPI) should replace histamine-2 receptor antagonists (H2RA). With our own intensive care unit (ICU) ceasing pharmacological stress ulcer prophylaxis two years ago (relying on enteral feeding alone to prevent such complications), we searched for burn injuryspecific guidance in the literature.
INTRODUCTION
Stress-related mucosal disease (SRMD) represents a continuum of pathology from superficial mucosal damage to full-thickness ulceration, induced by the physiological stress associated with critical illness. Curling's ulcer, associated with serious thermal injury, is morphologically similar to other stressrelated mucosal lesions, but can occur also in the oesophagus, stomach or small intestine 1 . SRMD and subsequent upper gastrointestinal (UGI) bleeding are associated with significant morbidity and mortality amongst critically ill patients 2 . Serious burn injury has been identified as a significant risk factor for gastric stress ulceration. However, such patients often have multiple contributing risk factors including sepsis, hypotension and major surgery, classifying them as high-risk patients 3 . Various mechanisms have been described which contribute to the pathogenesis of stress ulceration with the common final pathway of splanchnic hypoperfusion allowing back-diffusion of hydrogen ions and resultant mucosal damage.
Sucralfate, although not labelled for this indication, has been used for SRMD prophylaxis. It acts primarily to form a thin protective barrier lining the gastric mucosa, preventing mucosal damage from gastric acid 4 . It has been shown to be less effective in reducing clinically significant bleeding from SRMD than H2RAs 5 in a recent, large metaanalysis. Furthermore, difficult drug administration and impaired absorption of enteral feeds and coadministered medications have resulted in a trend away from this class of medication as first-line therapy 6 .
Prophylactic therapy with H2RAs to suppress gastric acid secretion has been shown to reduce the incidence of clinically significant UGI bleeding as a result of SRMD in critically ill patients 5 . This class of medication has been used widely in critical care medicine for this indication since the 1970s, with therapeutic guidelines formally published by the American Society of Health System Pharmacists in 1999 advocating this application 7 .
PPIs were subsequently introduced in the late 1980s. They represent an alternate method to suppress gastric acid production by irreversibly blocking the K + -H + -ATPase pump in gastric parietal cells. PPIs have been demonstrated to be superior in other conditions associated with acid secretion, including gastro-oesophageal reflux disease and Zollinger-Ellison syndrome 8 . This review was undertaken in order to investigate current evidence behind their potential to prevent clinically significant bleeding in SRMD.
Early enteral feeding has been shown to raise gastric pH and enhance regional distribution of gastrointestinal blood flow 9 and now plays a fundamental role in modern critical care medicine, especially in burns patients. This review encompasses an investigation into the role of early enteral feeding as prophylaxis against SRMD as the sole agent, and in combination with pharmacological therapies.
MATERIALS AND METHODS
PubMed and Cochrane databases were searched for relevant articles using keyword and text word search including stress ulcer, stress-related mucosal disease, burn injury, Curling's ulcer, upper gastrointestinal bleeding, proton pump inhibitor, histamine-2 receptor antagonist, pneumonia, burns and early enteral feeding. Where available, randomised controlled trials were preferentially used as these represent the highest level of clinical evidence.
Population
Included studies were conducted on an adult ICU patient population, including medical and surgical patients. Serious burn injury patients (involving >15% TBSA) were included in all studies; no studies specifically involving a burn patient population alone were identified. Furthermore, the admission diagnosis is not recorded for all included subjects, preventing identification of patients with thermal injuries. Articles involving purely paediatric patient populations have been excluded.
Intervention and comparator
The intervention under investigation was stress ulcer prophylaxis with PPI compared to H2RA in the prevention of UGI bleeding associated with SRMD. The role of antacids was not investigated in this review. This led to the subsequent analysis of the effect of early enteral feeding, with or without concomitant stress ulcer prophylaxis.
Outcome
The primary outcome was clinically significant UGI bleeding, defined as clinically significant bleeding necessitating transfusion of red cells, associated with haemodynamic compromise, or resulting in decrease of haemoglobin >20 g/l. Secondary outcome was the incidence of pneumonia as diagnosed on radiological examination.
RESULTS AND DISCUSSION
The literature review identified seven randomised, controlled trials (RCT) comparing H2RA and PPI in the prevention of UGI bleeding associated with SRMD [10] [11] [12] [13] [14] [15] [16] and three individual meta-analyses [17] [18] [19] . When evaluating early enteral feeding, a great proportion of the published literature involved retrospective reviews. One meta-analysis was identified 20 of 17 RCTs comparing H2RA to placebo with or without enteral feeding. This literature review highlights the opportunity for further research in this high-risk population.
Efficacy
PPIs have been shown to be effective in achieving gastric pH of >4.0, a level which has previously been found to be effective in preventing bleeding from SRMD 21 . A recent multi-centre randomised trial demonstrated that PPIs are more effective at maintaining a constant gastric pH >4.0 than the H2RA treatment group 16 . A further observation made during this study was the development of tolerance in the H2RA treatment group with a statistically significant decrease in acid control occurring within 42 hours after initial dose, confirming the phenomena of H2RA-related tolerance demonstrated in previous series 22 . However, while these properties suggest a preferable pharmacokinetic profile of PPIs, there is no conclusive evidence of a correlating decrease in clinically significant gastrointestinal bleeding.
Levy et al first published a prospective, randomised clinical trial comparing intravenous ranitidine and oral omeprazole in 67 patients in the ICU 11 . This study reported a significantly lower incidence of clinically significant UGI bleeding in omeprazole-treated subjects as compared to ranitidine-treated subjects (9 vs 31%). Although the two treatment groups had no statistically significant differences in terms of age, gender, race or Acute Physiological and Chronic Health Evaluation II score, the ranitidine subgroup had significantly more risk factors at base-line (2.7 vs 1.9). This inconsistency has been raised in subsequent discussion as a potential explanation for these results. Furthermore, the incidence of clinically significant gastrointestinal bleeding in this series was significantlygreater than in later trials. The early year of publication (1997) has been noted as a possible cause, as advances in critical care medicine such as early enteral feeding have been demonstrated to reduce SRMD 23 . These results were reproduced by a later prospective randomised trial published the following year, involving 58 ICU patients 12 . Again intravenous ranitidine and oral omeprazole were compared, with a significantly lower incidence of UGI bleeding in the PPI treatment group (3 vs 16%). However, in this series there were no significant differences in patient demographics or risk factors between the patient groups. These initial results have not been confirmed by subsequent meta-analyses. Lin et al analysed results from seven RCTs comparing PPIs with H2RAs for the prevention of UGI bleeding from SRMD in a total population of 936 patients 17 (Table 1) .
Trials included in this analysis involved adult patient populations in the ICU setting, with any PPI vs any H2RA, regardless of drug, dosage or route of administration. They found no significant difference in incidence of UGI bleeding between the treatment groups in accordance with results from other recently published RCTs 14 .
The other two meta-analyses published by Pongparsobchai et al and Zhou et al included a smaller number of the RCTs already evaluated in the meta-analysis by Lin [17] [18] [19] . These papers contained three and four RCTs respectively, resulting in a significantly smaller patient population. Both authors reported PPIs to be more effective than H2RAs in the prevention of clinically important bleeding (3.5 vs 8% 15 and 2.2 vs 6.8% 16 ). Given the inclusion criteria it is unclear why RCTs published during this time period by Phillips et al and Azvedo et al were excluded from these meta-analyses 12, 13 . This raises the question whether either provides comprehensive assessment of the current literature.
Safety
Stress ulcer prophylaxis is associated with increased colonisation of the UGI tract with potentially pathogenic gram-negative organisms 24 , and it is thought that multiple micro-aspirations of gastric contents with a higher bacterial load induced by acid suppression predispose patients to increased risk of pneumonia. Several small observational studies have been published supporting this theory 24, 25 . Therefore incidence of pneumonia may be an important marker of safety and consideration should be given as to which class of drug, if any, has a higher risk of this complication. However, no significant difference in incidence between control group patients and patients receiving acid suppressive therapy or sucralfate has been confirmed in the recent meta-analysis by Cook et al 5 . The PPI vs H2RA meta-analyses also failed to demonstrate a statistically significant difference in incidence of pneumonia in ICU patient populations [17] [18] [19] .
Adverse events
H2RAs are associated with a number of infrequent adverse effects. Central nervous system toxicity manifestations such as dizziness, somnolence, insomnia and vertigo have been documented at a frequency of 1.9%, with patients having impaired renal function at greater risk due to poor drug excretion 26 .
Haematological events including pancytopenia and agranulocytosis occur very rarely, with a frequency of 0.0023%, and are usually reversible with cessation of the medication 27 . Transient and reversible alterations in liver function tests have also been reported, as has acute hepatitis without jaundice. Similarly, cardiovascular toxicities such as tachycardia, bradycardia, premature ventricular beats and atrioventricular block have been reported in rare cases.
H2RAs are also involved in drug-drug interactions due to their potent inhibitory effect on the cytochrome oxidase enzyme system 28 . This commonly affects prothrombin time in association with coumarin anticoagulants such as warfarin, as well as increasing plasma levels of theophylline, metronidazole, imipramine, triazolam, diazepam, phenytoin, lignocaine, quinidine, nifedipine and propranolol.
On the other hand pantoprazole, a commonly used PPI due to its availability in enteral and parenteral formulations, has no known drug interactions, although other PPIs, including omeprazole and esomeprazole, do affect medications metabolised by the hepatic cytochrome P450 (such as diazepam, phenytoin and warfarin).
PPIs are extremely well tolerated. Minor adverse events including headache, diarrhoea, dizziness, pruritus and rash are infrequent and self-limiting 29 .
As stress-ulcer prophylaxis is discontinued when patients leave the acute care setting, patient noncompliance due to side-effects is not a consideration.
Cost
Cost of therapy is a further consideration when evaluating two potential treatments. This involves not only the monetary cost of the medication itself, but also the estimation of cost of staff labour time taken to prepare and administer it. This is difficult to quantify as both classes can be given as intravenous or oral formulations, in once, twice or thrice daily dosing. It is recommended to administer intravenous pantoprazole over two to 15 minutes; whereas intravenous ranitidine is administered as an intermittent infusion over two hours. However, it is not necessary that staff remain present during the entirety of the infusion, just to connect and disconnect the medication. It is thus likely that there is minimal difference in nursing time for administration.
Given that drug costs may be negotiable between supplier and purchaser, in Australia the Pharmaceutical Benefits Scheme listed price may be used as a guide. Five millilitres of intravenous ranitidine at a concentration of 10 mg/ml is listed as $26.41 for a pack of five. Based on a daily dosing of 150 mg/day, this equates to a daily expense of $15.85. On the other hand, 40 mg of intravenous pantoprazole is not listed as a Pharmaceutical Benefits Scheme medication and has been found to range in price, starting at $24.10 per vial. However, there is significant variability within the reported trials with regard to the particular drug used from each class, as well as the route of administration, dose and dosing interval, all of which will influence the final cost of therapy.
Early enteral feeding
Upper GI haemorrhage secondary to SRMD is a relatively uncommon complication in modern critical care medicine as demonstrated by the low incidence reported in the aforementioned series. This is of course partly due to pharmacological prophylaxis with agents such as PPIs and H2RAs, however the significant decline in incidence from 25% reported in 1978 21 cannot be attributed to this alone. Advances in critical care medicine including aggressive fluid resuscitation to minimise haemodynamic compromise and splanchnic hypoperfusion as well as early enteral feeding have been investigated to understand their role in prevention of SRMD.
Early enteral feeding has been established as a vital component of successful burns management. This not only aims to address the hypermetabolic state following thermal injury and thereby prevent catabolic metabolism and visceral protein loss 30 , it also helps to maintain intestinal barrier function and as such prevents bacterial translocation across the gut wall. This phenomenon was first demonstrated in experimental animal models 31 and subsequently confirmed in human studies 32 . In addition, enteral feeding has been shown to be more likely to raise gastric pH >3.5 than H2RAs or PPIs 33 . It was therefore suggested that early enteral feeding would be beneficial in preventing UGI bleeding secondary to SRMD.
Despite the apparent benefits of early enteral feeding, introduction into clinical practice was slow, largely due to concerns regarding safety and possible complications including increased vomiting and aspiration pneumonia. Several authors set out to dispel these concerns, publishing retrospective reviews of their own clinical experiences. A publication by McDonald et al consisted of 106 burn patients with greater than 20% TBSA burns who received early enteral feeding via nasogastric tube within six hours of thermal injury 34 .
Complication rates in this population were low, with 15% of patients (16 of 106) experiencing vomiting; despite this there was no recorded incidence of aspiration pneumonia. Furthermore, despite no prophylactic acid suppressive therapy, there was no incidence of UGI bleeding, prompting the authors to conclude that not only was early enteral feeding safe but was also effective in preventing UGI bleeding from SRMD. These promising results were corroborated by Raff et al in a retrospective review of 526 burns patients comparing enteral feeding with total parenteral nutrition and cimetidine with or without antacids. In this series the enterally fed group had a significantly lower incidence of UGI bleeding (3.3 vs 8.3%) 35 .
Lam et al conducted an RCT investigating the impact of early enteral feeding in severely burned patients with >40% TBSA 36 . Although designed to observe the immune and metabolic response to different nutritional regimens post burn injury by monitoring plasma levels of immunoglobulin G, immunoglobulin M, insulin and cortisol, secondary outcomes were also documented including GI bleeding. Of the 82 patients enrolled in the study, 41 received enteral nutrition within 24 hours of admission, with the remaining 41 patients remaining nil by mouth, supplemented with total parenteral nutrition. There was no incidence of GI haemorrhage in the enterally-fed subgroup, compared with 9.1% in the total parenteral nutrition subgroup. Furthermore, there was a lower incidence of pneumonia in the enterally-fed group (24.9 vs 41.5%). Unfortunately, the authors do not discuss whether any form of pharmacological prophylaxis was used.
A recent retrospective review of burn ICU patients found a lower incidence of GI haemorrhage in patients tolerating enteral feeding than in those who did not, 3 vs 31% respectively 37 . Only patients who failed to tolerate enteral feeds were prescribed a PPI, which was administered for at least three days, until feeds were tolerated. Unfortunately a small sample size (50 patients) limited the ability to examine the effect on hospital-acquired pneumonia.
However, this study has several limitations. First, as this is a retrospective review, patients were not randomised. Furthermore, patients who did not tolerate their feed had a significantly higher average burn severity index than those who did (11 vs 9) . Burn severity index has been shown to be an independent predictor of stress ulceration in previous studies 38 . It is therefore not possible to conclude decisively that the lower incidence of UGI bleeding is due to the prophylactic effect of enteral feeds, and is not in fact a reflection of the lower injury severity of this patient population.
Given that enteral feeding alone decreases the risk of clinically significant UGI bleeding, does additional pharmacological prophylaxis have a summative, synergistic or detrimental effect on the patient? This question was investigated in a meta-analysis published by Marik et al in a general ICU patient population 20 . Seventeen studies were included for analysis with a total population of 1836 patients. In keeping with previous results, treatment with H2RA reduced the risk of UGI bleeding (odds ratio 0.47, 95% confidence interval). When comparing patients receiving enteral feeds with or without additional H2RA prophylaxis (three studies with a total patient population of 262) [39] [40] [41] , no difference in the risk of UGI bleeding was observed (odds ratio 1.26, 95% confidence interval). Furthermore, the subgroup of patients receiving H2RA and enteral feeds had an increased risk of hospital-acquired pneumonia (odds ratio 2.81, 95% confidence interval). This is attributed to the increased gastric pH due to acid suppressive therapy and enteral feeding, which is significantly higher than with either intervention alone, resulting in increased gastric bacterial colonisation 33 .
The authors of this meta-analysis concluded that in patients receiving enteral feeding, stress ulcer prophylaxis may not be required, and combined therapy may even increase the risk of hospitalacquired pneumonia. The data are summarised in Table 2 .
CONCLUSIONS
This review encompasses seven RCTs and three meta-analyses comparing H2RAs and PPIs in the prevention of UGI bleeding secondary to SRMD, as well as three RCTs and one meta-analysis evaluating the role of early enteral feeding as prophylaxis. At Level 1 clinical evidence, no significant difference in efficacy between the two treatment groups was demonstrated. Similarly, there was no significant difference demonstrated in the incidence of nosocomial pneumonia. As such, adverse events, ease of administration and cost-effectiveness become determinant factors in drug choice.
However, the weight of burns literature evaluating early enteral feeding suggests that this practice is not only safe, but also an effective method of preventing SRMD in retrospective reviews. This is supported by Level 1 clinical evidence from general ICU patients which suggests that in addition, while there appears to be no added benefit of pharmacological acid suppressive therapy, there may be a detrimental predisposition to nosocomial pneumonia. There remain, however, no randomised, controlled clinical trials specifically in a burn patient population that compare enteral feeding against no feeding.
Since all burn patients at the Royal Adelaide Hospital are fed from very early in their admission, the literature suggests that we, like our ICU colleagues, should abolish our reliance on pharmacological prophylaxis, the routine prescription of which is not evidence-supported. This proposed change in management should be tempered in the knowledge that it is drawn from a small burns patient sample size, and larger populations are required to obtain sufficient power to support these conclusions. Enteral feeds 100 6 (6.0%) 6 (6.0%)
UGI=upper gastrointestinal, CIV=continuous intravenous infusion, N/A=not assessed, IV=intravenous infusion.
